{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:19:00Z","timestamp":1780582740132,"version":"3.54.1"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0228648","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T13:45:03Z","timestamp":1580823903000},"page":"e0228648","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Prolactin response to antipsychotics: An inpatient study"],"prefix":"10.1371","volume":"15","author":[{"given":"Liana","family":"Dehelean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-2088","authenticated-orcid":true,"given":"Ana-Maria","family":"Romosan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ion","family":"Papava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Ana","family":"Bredicean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Dumitrascu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorin","family":"Ursoniu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6823-5277","authenticated-orcid":true,"given":"Radu-Stefan","family":"Romosan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"issue":"9","key":"pone.0228648.ref001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","article-title":"Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns","volume":"19","author":"B Vitiello","year":"2009","journal-title":"European Neuropsychopharmacology"},{"issue":"5_suppl","key":"pone.0228648.ref002","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0269881112442016","article-title":"Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis","author":"J Cookson","year":"2012","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"pone.0228648.ref003","first-page":"229","article-title":"Hyperprolactinemia in association with subclinical hypothyroidism","volume":"2","author":"A Bahar","year":"2011","journal-title":"Caspian journal of internal medicine"},{"issue":"5","key":"pone.0228648.ref004","first-page":"929","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"D La Torre","year":"2007","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"12","key":"pone.0228648.ref005","doi-asserted-by":"crossref","first-page":"e82749","DOI":"10.1371\/journal.pone.0082749","article-title":"Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study","volume":"8","author":"S Kim","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"pone.0228648.ref006","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archpsyc.1974.01760160102021","article-title":"Serum prolactin levels in unmedicated schizophrenic patients","volume":"31","author":"HY Meltzer","year":"1974","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"pone.0228648.ref007","first-page":"205","article-title":"Diagnosis of stress-related hyperprolactinemia. Evaluation of the hyperprolactinemia rest test","volume":"89","author":"O Muneyyirci-Delale","year":"1989","journal-title":"New York state journal of medicine"},{"issue":"1","key":"pone.0228648.ref008","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/eje.0.1510061","article-title":"Life events in the pathogenesis of hyperprolactinemia","volume":"151","author":"N Sonino","year":"2004","journal-title":"European journal of endocrinology"},{"issue":"3","key":"pone.0228648.ref009","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.psychres.2004.01.010","article-title":"Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes","volume":"127","author":"M Segal","year":"2004","journal-title":"Psychiatry research"},{"issue":"3","key":"pone.0228648.ref010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1192\/bjp.182.3.199","article-title":"Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: selective literature review","volume":"182","author":"A Wieck","year":"2003","journal-title":"The British Journal of Psychiatry"},{"key":"pone.0228648.ref011","article-title":"Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia","author":"L Vilar","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"3","key":"pone.0228648.ref012","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.rpsmen.2016.06.001","article-title":"Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia","volume":"9","author":"AL Montejo","year":"2016","journal-title":"Revista de Psiquiatr\u00eda y Salud Mental (English Edition)"},{"key":"pone.0228648.ref013","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yfrne.2017.02.003","article-title":"Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics","volume":"45","author":"\u00c1L Montejo","year":"2017","journal-title":"Frontiers in Neuroendocrinology"},{"issue":"4","key":"pone.0228648.ref014","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"S Kapur","year":"2000","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"pone.0228648.ref015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1001\/archpsyc.1978.01770250110011","article-title":"Prolactin responses to neuroleptics in normal and schizophrenic subjects","volume":"35","author":"PH Gruen","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"10","key":"pone.0228648.ref016","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1001\/archpsyc.1978.01770340072008","article-title":"Relation of plasma prolactin to clinical response in schizophrenic patients","volume":"35","author":"PH Gruen","year":"1978","journal-title":"Archives of general psychiatry"},{"issue":"3","key":"pone.0228648.ref017","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archpsyc.1976.01770030003001","article-title":"The effect of neuroleptics on serum prolactin in schizophrenic patients","volume":"33","author":"HY Meltzer","year":"1976","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"pone.0228648.ref018","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0165-1781(02)00022-7","article-title":"Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia","volume":"109","author":"XY Zhang","year":"2002","journal-title":"Psychiatry research"},{"issue":"4","key":"pone.0228648.ref019","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1600-0447.2006.00897.x","article-title":"Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders","volume":"115","author":"J Eberhard","year":"2007","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"pone.0228648.ref020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-3223(94)91147-9","article-title":"Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia","volume":"35","author":"ML Rao","year":"1994","journal-title":"Biological Psychiatry"},{"key":"pone.0228648.ref021","article-title":"Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients","author":"SV Faraone","year":"1987","journal-title":"The Journal of clinical psychiatry"},{"key":"pone.0228648.ref022","first-page":"569","author":"WA Brown","year":"1984"},{"issue":"12","key":"pone.0228648.ref023","doi-asserted-by":"crossref","first-page":"964","DOI":"10.4088\/JCP.v61n1213","article-title":"Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum","volume":"61","author":"DL Garver","year":"2000","journal-title":"The Journal of clinical psychiatry"},{"issue":"10","key":"pone.0228648.ref024","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0006-3223(91)90353-N","article-title":"Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome","volume":"29","author":"R Tandon","year":"1991","journal-title":"Biological Psychiatry"},{"issue":"1","key":"pone.0228648.ref025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1192\/bjp.185.1.5","article-title":"Pituitary volume in psychosis","volume":"185","author":"CM Pariante","year":"2004","journal-title":"The British Journal of Psychiatry"},{"key":"pone.0228648.ref026","first-page":"1283","author":"C Lum","year":"2002"},{"issue":"7","key":"pone.0228648.ref027","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1001\/archpsyc.1987.01800190020003","article-title":"Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia","volume":"44","author":"F Karoum","year":"1987","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"pone.0228648.ref028","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/0893-133X(95)00200-W","article-title":"Psychobiologic correlates of treatment response in schizophrenia","volume":"14","author":"JA Lieberman","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"pone.0228648.ref029","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0165-1781(81)90078-0","article-title":"Tolerance to the prolactin-elevating effect of neuroleptics","volume":"5","author":"WA Brown","year":"1981","journal-title":"Psychiatry research"},{"key":"pone.0228648.ref030","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/978-1-4684-4529-9_34","volume-title":"InPsychoneuroendocrine Dysfunction","author":"D Naber","year":"1984"},{"issue":"3","key":"pone.0228648.ref031","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2265.1976.tb01953.x","article-title":"Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups","volume":"5","author":"JD Rivera","year":"1976","journal-title":"Clinical endocrinology"},{"key":"pone.0228648.ref032","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinemia","volume":"80","author":"ME Molitch","year":"2005","journal-title":"In Mayo Clinic Proceedings"},{"issue":"3","key":"pone.0228648.ref033","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"JE Overall","year":"1962","journal-title":"Psychological reports"},{"key":"pone.0228648.ref034","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects","volume":"28","author":"U Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"pone.0228648.ref035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"FF Casanueva","year":"2006","journal-title":"Clinical endocrinology"},{"key":"pone.0228648.ref036","author":"DM Taylor","year":"2018"},{"issue":"2","key":"pone.0228648.ref037","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/0019-5545.111475","article-title":"Current perspectives on chlorpromazine equivalents: comparing apples and oranges!","volume":"55","author":"V Danivas","year":"2013","journal-title":"Indian journal of psychiatry"},{"issue":"11","key":"pone.0228648.ref038","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics","volume":"21","author":"PM Haddad","year":"2007","journal-title":"CNS drugs"},{"issue":"10","key":"pone.0228648.ref039","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/00048674.2011.589044","article-title":"Antipsychotic-induced hyperprolactinaemia","volume":"45","author":"WJ Inder","year":"2011","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"9","key":"pone.0228648.ref040","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4088\/JCP.08m04307yel","article-title":"Positron emission tomography measurement of dopamine D\u2082 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia","volume":"71","author":"R Arakawa","year":"2010","journal-title":"The Journal of clinical psychiatry"},{"issue":"4","key":"pone.0228648.ref041","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","article-title":"Hyperprolactinemia associated with psychotropics\u2014a review","volume":"25","author":"S Madhusoodanan","year":"2010","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"3","key":"pone.0228648.ref042","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00213-004-1826-6","article-title":"Prolactinemia is uncoupled from central D 2\/D 3 dopamine receptor occupancy in amisulpride treated patients","volume":"175","author":"RA Bressan","year":"2004","journal-title":"Psychopharmacology"},{"issue":"1","key":"pone.0228648.ref043","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/157488711793980138","article-title":"Recent clinical aspects of hyperprolactinemia induced by antipsychotics","volume":"6","author":"W Milano","year":"2011","journal-title":"Reviews on recent clinical trials"},{"issue":"5","key":"pone.0228648.ref044","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00131746-200309000-00003","article-title":"Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects","volume":"9","author":"U Halbreich","year":"2003","journal-title":"Journal of Psychiatric Practice\u00ae"},{"issue":"11","key":"pone.0228648.ref045","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","article-title":"Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"J Montgomery","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"pone.0228648.ref046","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00128-2","article-title":"Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials","volume":"28","author":"BJ Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"pone.0228648.ref047","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2265.2003.01694.x","article-title":"Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization","volume":"58","author":"W Raber","year":"2003","journal-title":"Clinical endocrinology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T13:46:19Z","timestamp":1580823979000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228648"}},"subtitle":[],"editor":[{"given":"Kenji","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0228648","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]}}}